FLAP

Product Specifications

Background

Seems to be required for the activation of 5-LO (5-lipoxygenase). Could play an essential role in the transfer of arachidonic acid to 5-LO. Binds to MK-886, a compound that blocks the biosynthesis of leukotrienes. Genetic variations in FLAP may be a cause of susceptibility to ischemic stroke [MIM:601367]; also known as cerebrovascular accident or cerebral infarction. A stroke is an acute neurologic event leading to death of neural tissue of the brain and resulting in loss of motor, sensory and/or cognitive function. Ischemic strokes, resulting from vascular occlusion, is considered to be a highly complex disease consisting of a group of heterogeneous disorders with multiple genetic and environmental risk factors.

Synonyms

FLAP, Arachidonate 5-lipoxygenase-activating Protein, MK 886 Binding Protein

UniProt

P20292 (Human)

Host

Rabbit

Species Reactivity

Human

Conjugation

Unconjugated

Type

Blocking Peptide

Applications

Assay Principle

For use with FLAP polyclonal antibodies (Cat. No. X2318P , X2350P).

Stability

See expiration date on vial

Concentration

See vial for Concentration

Form

Provided as solution in phosphate buffered saline

Precautions

This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving Humans or animals.

References & Citations

1. Dixon, R.A.F., et al. 'Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis.; Nature 343:282-284(1990). 2. Helgadottir, A., et al. 'The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke.; Nat. Genet. 36:233-239(2004).